-
1
Targeted therapies for autoimmune diseases include bDMARDs, tsDMARDs, and CAR-T therapy, improving disease control and long-term outcomes.
-
2
Risk management programs (RMPs) are essential for addressing safety concerns associated with targeted therapies, including infection screening and prophylaxis.
-
3
Real-world adherence to RMPs may vary, particularly after treatment initiation and during transitions to biosimilars.
-
4
The study evaluated RMP adherence and its association with infection-related outcomes in patients receiving targeted therapies.
-
5
Primary outcomes of interest included Pneumocystis jirovecii pneumonia, major adverse cardiovascular events, and all-cause mortality.
